Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy

Oncology Reports

Volumn 10, Issue 4, 2003, Pages 851-857

  Bacci, Gaetano ^a   Ferrari, Stefano ^a   Longhi, Alessandra ^a   Forni, Cristiana ^a   Loro, Loretta ^a   Beghelli, Claudio ^a   Tremosini, Morena ^a   Versari, Michela ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Methotrexate; Neoadjuvant chemotherapy; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; BONE TUMOR; CHILD; FEMALE; HUMAN; MALE; METABOLIC CLEARANCE RATE; METABOLISM; OSTEOSARCOMA; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; LEUCOVORIN; MALE; METABOLIC CLEARANCE RATE; METHOTREXATE; NEOADJUVANT THERAPY; OSTEOSARCOMA; RETROSPECTIVE STUDIES;

EID: 1542472976     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.4.851     Document Type: Article

References (37)

1. Rosen G: Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopaedics 8: 659-664, 1985.
2. Delepine N, Delepine G, Bacci G, Rosen G and Desbois JC: Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. An analysis of literature. Cancer 78: 2127-2135, 1996. (Pubitemid 26367605)
3. Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15: 76-84, 1997. (Pubitemid 27020560)
4. Fuchs N, Bielack SS, Epler D, et al: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotehrapy and surgery for osteosarcoma of the limbs. Ann Oncol 9: 893-899, 1998. (Pubitemid 28440449)
5. Meyers PA, Gorllick R, Heller G, et al: Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T-12) protocol. J Clin Oncol 16: 2452-2458, 1998. (Pubitemid 28309040)
6. Saeter G, Wiebe T, Wiklund T, et al: Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand 285: 74-82, 1999. (Pubitemid 29329084)
7. Aparicio J, Segura A, Montalar J, et al: Long-term results after combined modality of treatment for non-metastatic osteosarcoma. Med Oncol 16: 255-260, 1999. (Pubitemid 30055714)
8. Bacci G, Briccoli A, Ferrari S, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long term results of the Rizzoli's 4th protocol. Eur J Cancer 37: 2030-2039, 2001. (Pubitemid 32938106)
9. Yap HY, Blumenschein GR, Yap BS, et al: High-dose methotrexate for advanced breast cancer. Cancer Treat Rep 63: 757-761, 1979. (Pubitemid 9248168)
10. Frei E, Blum RH, Pitman SW, et al: High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Ann J Med 68: 370-376, 1980. (Pubitemid 10130377)
11. Ackland SP and Schilsky RL: High dose methotrexate: a critical reappraisal. J Clin Oncol 5: 2017-2031, 1987. (Pubitemid 18010164)
12. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM and Pui CH: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338: 499-505, 1998. (Pubitemid 28103133)
13. Ferreri AJ, Reni M and Villa E: Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 11: 927-937, 2000.
14. Bleyer WA: Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4: 87-101, 1977.
15. Abelson HT, Fosburg MT, Beardsley GP, et al: Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high dose leucovorin rescue and thymidine. J Clin Oncol 1: 208-216, 1983. (Pubitemid 14245668)
16. Takemi M, Kuniyoshi Y, Oomukai T, Ishida T and Yamano Y: Severe complications after high-dose methotrexate treatment. Acta Oncol 34: 611-612, 1995.
17. Stark AN, Jackson G, Carey PJ, Arfeen S and Proctor SJ: Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol 24: 243-245, 1989. (Pubitemid 19176806)
18. Stoller RG, Handke KR, Jacobs SA, Rosenberg SA and Chabner BA: Use of plasma pharmacokinetics to predict and prevent methotrexate N Engl J Med 297: 630-634, 1977. (Pubitemid 8200049)
19. Widemann BC, Balis FM, Murphy RF, et al: Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 15: 2125-2134, 1997. (Pubitemid 27209546)
20. Jurgens H, Beron G and Winkler K: Toxicity associated with combination chemotherapy for osteosarcoma: a report of the cooperative osteosarcoma study (COSS-80). J Cancer Res Clin Oncol 106: 14-18, 1983. (Pubitemid 13040816)
21. Kobayashi H, Morita T, Hirata Y, Kato T and Sato T: Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion - a case report. Gan To Kagaku Ryoho 27: 475-478, 2000.
22. Shinozaki T, Watanabe H, Tomidokoro R, Yamamoto K, Horiuchi R and Takagishi K: Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: non-renal excretion of serum methotrexate. Med Pediatr Oncol 34: 226-228, 2000. (Pubitemid 30132151)
23. Flombaum CD and Meyers PA: High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 17: 1589-1594, 1999. (Pubitemid 29220869)
24. Bacci G, Ferrari S, Bertoni F, et al: Long-term outcome for patients with non-metastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to IOR/OS-2 protocol: an updated report. J Clin Oncol 18: 4016-4027, 2000. (Pubitemid 32038393)
25. Bacci G, Picci P, Ruggieri P, et al: Primary chemotherapy and delayed surgery (neoadjuvant chemotharapy) for osteosarcoma of the extremities. The Istituto Ortopedico Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intra-arterial cisplatin. Cancer 65: 2539-2553, 1990.
26. Ferrari S, Mercuri M, Picci P, et al: Non-metastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intr-arterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 85: 458-464, 1999.
27. Bacci G, Ferrari S, Longhi A, et al: High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother (In press).
28. Fleisher M and Schwartz MK: Measurement of anti-folate analogs. Clin Chem 38: 609-610, 1992.
29. Jaffe N, Goorin A, Link M, et al: High-dose methotrexate in osteogenic sarcoma adjuvant and neoadjuvant chemotherapy and limb salvage results. Cancer Treat Rep 65: 99-106, 1981. (Pubitemid 12160481)
30. Pitman SW, Parker LM, Tattersall MHN, Jaffe N and Frei E: Clinical trial of high dose methotrexate (NSC-740) with citrovorum factor (NSC-3590): toxicologic and therapeutic observations. Cancer Chemother Rep 6: 43-49, 1975.
31. Chan H, Evans WE and Pratt CB: Recovery from toxicity associated with high dose methotrexate: prognostic factors. Cancer Treat Rep 61: 797-804, 1977. (Pubitemid 8167605)
32. Rosen G and Nirenberg A: Neoadjuvant chemotehrapy for osteogenic sarcoma: a five-year follow-up (T-10) and preliminary report of new studies (T-12). Prog Clin Biol Res 201: 39-51, 1985.
33. Pinedo HM, Zaharko DS, Bull JM and Chabner BA: The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 36: 4418-4424, 1976.
34. Frappaz D, Bouffet E, Cochat P, et al: Hemoperfusion on charcoal and hemodialysis in acute poisoning caused by methotrexate. Presse Med 17: 1209-1213, 1988.
35. Molina R, Fabian C and Cowley B: Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med 82: 350-352, 1987.
36. Relling MV, Stapleton FB, Ochs J, et al: Removal of methotrexate, leucovorin and their metabolites by combined hemodialysis and hemoperfusion. Cancer 62: 884-888, 1988.
37. De Angelis LM, Tong WP, Lin S, Fleischer M and Bertino JR: Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol 14: 2145-2149, 1996.